Amphastar Pharmaceuticals, Inc. (AMPH) research
Amphastar Pharmaceuticals, Inc.- Sector
- Pharmaceuticals
- Last price
- $25.37
- As of
Kresmion compiles this page from AMPH's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Amphastar Pharmaceuticals, Inc. (AMPH): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for AMPH. Method and limitations.
Share the AMPH intelligence card
See the full AMPH dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AMPH on one page. Preview it with sample data, then open it live with a free account.
Preview the AMPH dossierActive signals for AMPH
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 43.9%, EPS $0.91 vs $0.6325 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of AMPH (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 95% of AMPH (2026Q2)
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in AMPH
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 91% of AMPH (2026Q2)
FREE, NO ACCOUNT
Every signal on AMPH, as it fires
You are seeing 5 of 11 signals recorded on AMPH since 2026-05-16.
The five above landed across 2 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AMPH (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 03209R103 · 2026Q2 | $17.9M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03209R103 · 2026Q2 | $10.6M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03209R103 · 2026Q2 | $5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 03209R103 · 2026Q2 | $1.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03209R103 · 2026Q2 | $642K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03209R103 · 2026Q2 | $328K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AMPH
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AMPH against its peers
AMPH's operating margin of 19.5% ranks in the 81st percentile of 17 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | AMPH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 720M USD | 407M USD | 64 | 20 |
| Gross margin | 49.5% | 59.3% | 25 | 5 |
| Operating margin | 19.5% | 2.6% | 81 | 17 |
| Net margin | 13.6% | -2.6% | 87 | 18 |
| Return on equity | 12.4% | -20.4% | 72 | 22 |
| P / E | 12.5x | 15.0x | 17 | 8 |
Peers (25): ANRO, PCRX, ALMS, OMER, ESPR, PAHC, INVA, OCUL, ACRS, XERS, ANIP, COLL, NUVB, TRVI, NKTR, BHC, GPCR, HRMY, SUPN, AVIR, BIOA, OGN, TARS, AMLX, FULC. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AMPH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AMPH on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AMPH for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.